SG11201607484RA - Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein - Google Patents
Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoproteinInfo
- Publication number
- SG11201607484RA SG11201607484RA SG11201607484RA SG11201607484RA SG11201607484RA SG 11201607484R A SG11201607484R A SG 11201607484RA SG 11201607484R A SG11201607484R A SG 11201607484RA SG 11201607484R A SG11201607484R A SG 11201607484RA SG 11201607484R A SG11201607484R A SG 11201607484RA
- Authority
- SG
- Singapore
- Prior art keywords
- bind
- antibodies against
- igm antibodies
- associated glycoprotein
- carbohydrate ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/10—Esters
- C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
- G01N33/04—Dairy products
- G01N33/06—Determining fat content, e.g. by butyrometer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14159528 | 2014-03-13 | ||
| PCT/EP2015/055140 WO2015136027A1 (fr) | 2014-03-13 | 2015-03-12 | Ligands glucidiques qui se lient aux anticorps igm contre la glycoprotéine associée à la myéline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607484RA true SG11201607484RA (en) | 2016-10-28 |
Family
ID=50241299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607484RA SG11201607484RA (en) | 2014-03-13 | 2015-03-12 | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9994605B2 (fr) |
| EP (2) | EP3116887B1 (fr) |
| JP (1) | JP6502374B2 (fr) |
| KR (1) | KR20160132034A (fr) |
| CN (2) | CN106103461B (fr) |
| AU (2) | AU2015228870B2 (fr) |
| CA (1) | CA2940579A1 (fr) |
| CY (1) | CY1124344T1 (fr) |
| DK (1) | DK3116887T3 (fr) |
| ES (1) | ES2865148T3 (fr) |
| HR (1) | HRP20210562T1 (fr) |
| HU (1) | HUE054034T2 (fr) |
| IL (1) | IL247355B (fr) |
| LT (1) | LT3116887T (fr) |
| MX (1) | MX2016011859A (fr) |
| PL (1) | PL3116887T3 (fr) |
| PT (1) | PT3116887T (fr) |
| RS (1) | RS61722B1 (fr) |
| RU (1) | RU2760005C2 (fr) |
| SG (1) | SG11201607484RA (fr) |
| SI (1) | SI3116887T1 (fr) |
| WO (1) | WO2015136027A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2940579A1 (fr) | 2014-03-13 | 2015-09-17 | Universitaet Basel | Ligands glucidiques qui se lient aux anticorps igm contre la glycoproteine associee a la myeline |
| EP3350193B1 (fr) * | 2015-09-16 | 2020-12-23 | Universität Basel | Ligands glucidiques qui se lient à des anticorps contre des glycoepitopes de glycosphingolipides |
| CN110545851A (zh) * | 2017-03-15 | 2019-12-06 | 泛欧制药公司 | 螯合碳水化合物结合蛋白的糖聚合物 |
| EP3715376A1 (fr) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Composé pour la prévention ou le traitement de la myasthénie grave |
| EP3715374A1 (fr) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Composé de séquestration d'anticorps indésirables chez un patient |
| EP3715375A1 (fr) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Composé pour la prévention ou le traitement de la pré-éclampsie |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| US20230381334A1 (en) | 2020-09-23 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物 |
| CN116669755A (zh) | 2020-09-23 | 2023-08-29 | 艾柏力维亚生技有限公司 | 用于增加因子viii替代疗法的效力的化合物 |
| JP2023542390A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | ウイルスベクターの有効性を増強するための化合物 |
| JP2023542389A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | 自己抗体で媒介される状態の予防又は治療のための化合物 |
| WO2022063880A1 (fr) | 2020-09-24 | 2022-03-31 | Ablevia Biotech Gmbh | Composé pour prévenir ou traiter la myasthénie grave |
| WO2023180502A1 (fr) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Composé pour augmentation de l'efficacité des virus oncolytiques |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2811494B2 (ja) | 1990-03-14 | 1998-10-15 | 富士写真フイルム株式会社 | キトサンまたはキチン化合物を含有するハロゲン化銀写真感光材料およびこれを用いるハロゲン化銀写真感光材料の処理方法 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| JPH07502011A (ja) | 1991-06-10 | 1995-03-02 | グライカムド インコーポレイテッド | 免疫抑制性および寛容原性のオリゴ糖誘導体 |
| AU2484892A (en) | 1991-08-09 | 1993-03-02 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| US5985578A (en) | 1991-08-09 | 1999-11-16 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| US6020140A (en) | 1991-08-09 | 2000-02-01 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| US5651968A (en) | 1991-08-23 | 1997-07-29 | Alberta Research Council | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| EP0601417A3 (fr) | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologiquement compatible et dégradable bloques de récepteur d'hydrate de carbone à base de polymère, procédé de leur préparation et leur utilisation |
| US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
| CA2133772A1 (fr) | 1993-11-19 | 1995-05-20 | Yuji Yamada | Methode et reactif pour l'essai de glycoconjugues |
| DE19526675A1 (de) | 1994-09-09 | 1996-03-14 | Herbert Prof Dr Wiegandt | Teststreifenanalyse zur Erfassung von autoallergen menschlichen Pathologien |
| FR2727117A1 (fr) | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| WO1997007810A1 (fr) * | 1995-08-25 | 1997-03-06 | The John Hopkins University School Of Medicine | Composes pour stimuler la croissance du tissu nerveux |
| DE19531346A1 (de) * | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen |
| US5874411A (en) | 1995-11-13 | 1999-02-23 | Glycomed Incorporated | Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties |
| WO1997019105A1 (fr) | 1995-11-21 | 1997-05-29 | Novartis Ag | Polymeres polyvalents, leurs procedes de preparation et leur utilisation pour preparer des composes biologiquement actifs |
| US6491922B1 (en) | 1996-02-09 | 2002-12-10 | Cornell Research Foundation, Inc. | Methods and compounds for treating autoimmune and vascular disease |
| DE69835201T2 (de) | 1997-04-18 | 2007-06-14 | Novartis Ag | Neoglycoproteine |
| FR2762602B1 (fr) | 1997-04-28 | 1999-06-04 | Inst Nat Sante Rech Med | Moyens pour la detection precoce de pathologies auto-immunes inflammatoires |
| US6077681A (en) | 1997-06-30 | 2000-06-20 | Washington University | Diagnosis of motor neuropathy by detection of antibodies |
| HUP0003418A2 (hu) | 1997-09-05 | 2001-02-28 | Glycim Oy | Szintetikus, kétértékű, sLex-tartalmú polilaktózaminok és eljárás előállításukra |
| AU761831B2 (en) | 1998-04-15 | 2003-06-12 | Bioscience 2002 Llc | Inhibition of xenoreactive antibodies |
| CA2329495A1 (fr) | 1998-04-22 | 1999-10-28 | Merck & Co., Inc. | Fragments auto-antigenes, methodes et dosages |
| CA2332571A1 (fr) | 1998-06-30 | 2000-01-06 | Mochida Pharmaceutical Co., Ltd. | Nouveau peptide lie par une chaine de sucres et similaire a la thrombomoduline |
| US6228598B1 (en) * | 1998-10-02 | 2001-05-08 | Washington University | Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies |
| EP1133521A1 (fr) | 1998-11-16 | 2001-09-19 | Genetics Institute, Inc. | Chimiokine cxc h174 et techniques permettant de prevenir des lesions du systeme nerveux |
| WO2000033887A2 (fr) | 1998-12-08 | 2000-06-15 | La Jolla Pharmaceutical Company | Procedes et formulations permettant de reduire des anticorps circulants |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| WO2000050447A1 (fr) | 1999-02-24 | 2000-08-31 | Acorda Therapeutics | Peptides mimetiques d'epitope glucidique et utilisations correspondantes |
| DE19930177B4 (de) | 1999-06-30 | 2007-02-08 | Nikolai Vladimirovich Bovin | Intermolekular assoziierende Verbindungen und deren Verwendung |
| US6994970B1 (en) | 1999-09-21 | 2006-02-07 | Fresenius Medical Care Affina Gmbh | Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (DCM) |
| EP1311549A2 (fr) | 2000-08-22 | 2003-05-21 | Micromet AG | Composition destinee a l'elimination des cellules b autoreactives |
| AU2001288431A1 (en) | 2000-08-28 | 2002-03-13 | The Trustees Of Columbia University In The City Of New York | Detection of anti-glycolipid antibodies by latex agglutination assay |
| ATE368688T1 (de) | 2000-11-08 | 2007-08-15 | Fresenius Medical Care Affina | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen |
| US6730487B2 (en) | 2001-04-03 | 2004-05-04 | Trustees Of Columbia University In The City Of New York | Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy |
| DE10127712A1 (de) | 2001-06-07 | 2002-12-19 | Torsten Witte | Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis |
| EP1411952B1 (fr) | 2001-06-29 | 2009-04-22 | Glykos Finland Oy | Utilisation d'au moins une substance glyco-inhibitrice contre les maladies contagieuses |
| EP1474451A2 (fr) | 2002-02-13 | 2004-11-10 | Micromet AG | Constructions (poly)peptidiques desimmunisees |
| WO2004015420A1 (fr) | 2002-08-02 | 2004-02-19 | Glycominds Ltd. | Procede de diagnostic de sclerose en plaques |
| TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| RU2303461C9 (ru) * | 2002-08-06 | 2007-12-27 | Глаксо Груп Лимитед | Антитела против миелин-ассоциированного гликопротеина (mag) |
| US7175989B2 (en) * | 2002-08-20 | 2007-02-13 | Alan Pestronk | Antibodies to trisulfated heparin disaccharide in painful sensory axonal neuropathy |
| US20040043431A1 (en) | 2002-08-29 | 2004-03-04 | Aristo Vojdani | Diagnosis of multiple sclerosis and other demyelinating diseases |
| US20030049692A1 (en) | 2002-09-16 | 2003-03-13 | Norman Latov | Detection of anti-glycolipid antibodies by latex agglutination assay |
| RU2389732C2 (ru) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
| WO2004065400A1 (fr) | 2003-01-20 | 2004-08-05 | Glykos Finland Oy | Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes |
| US9050352B2 (en) | 2003-10-16 | 2015-06-09 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
| DE602004011272T2 (de) | 2003-11-19 | 2008-12-24 | Glycomimetics, Inc. | Spezifischer antagonist sowohl für e- als auch p-selektine |
| WO2005051429A2 (fr) | 2003-11-19 | 2005-06-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Systeme d'administration ciblee pour agents bioactifs |
| EP1685145A2 (fr) | 2003-11-19 | 2006-08-02 | GlycoMimetics, Inc. | Antagonistes glycomimetiques pour les selectines de type e et p |
| US20050272097A1 (en) | 2004-02-18 | 2005-12-08 | Emanuel Calenoff | Methods and compositions for detecting and treating autoimmune diseases |
| CN103788141B (zh) | 2004-03-04 | 2016-08-17 | 普罗吉恩制药有限公司 | 硫酸化寡聚糖衍生物 |
| WO2005118609A2 (fr) | 2004-05-26 | 2005-12-15 | California Institute Of Technology | Petits stimulateurs de molecules de croissance neuronale |
| CA2582668C (fr) | 2004-10-01 | 2013-10-01 | Midatech Ltd | Nanoparticules comprenant des antigenes et des adjuvants et structures immunogenes |
| CN101123990A (zh) | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒，和免疫原性结构 |
| WO2006068720A2 (fr) | 2004-11-12 | 2006-06-29 | The Brigham And Women's Hospital, Inc. | Polypeptides de ligands de selectine des cellules hematopoietiques et procedes d'utilisation de ces polypeptides |
| US7884260B2 (en) | 2005-06-14 | 2011-02-08 | University Of Chicago | Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination |
| JP4619873B2 (ja) * | 2005-06-20 | 2011-01-26 | 独立行政法人産業技術総合研究所 | グルクロニル硫酸化２糖誘導体 |
| US8431160B2 (en) | 2006-02-24 | 2013-04-30 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
| WO2007120815A2 (fr) | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Procedes destines au traitement de troubles lymphocytaires par modulation de l'activite siglec |
| GB0610350D0 (en) | 2006-05-25 | 2006-07-05 | Univ Liverpool | prevention and/or treatment of neuodegenerative disorders |
| US8420593B1 (en) | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| US20090175792A1 (en) | 2006-06-23 | 2009-07-09 | Glycomimetics, Inc. | Glycomimetic inhibitors of siglec-8 |
| PL2061810T3 (pl) | 2006-09-05 | 2015-05-29 | Alexion Pharma Inc | Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał |
| GB0622688D0 (en) | 2006-11-14 | 2006-12-27 | Diosamine Dev Corp | Novel compounds |
| CN101678090B (zh) | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| US20080220988A1 (en) | 2007-03-07 | 2008-09-11 | Ada Technologies, Inc. | Preparing carbohydrate microarrays and conjugated nanoparticles |
| WO2008151847A1 (fr) | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Peptides de liaison aux autoanticorps et leur utilisation pour le traitement de maladies vasculaires |
| JP2010535211A (ja) | 2007-08-02 | 2010-11-18 | アンティソーマ ベンチャーズ リミテッド | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 |
| CA2708246C (fr) | 2007-12-05 | 2016-05-24 | Wittycell | Compositions et methodes destinees a ameliorer la reponse immunitaire aux antigenes |
| WO2009102820A2 (fr) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Substrats à base de sucres modifiés et procédés d’utilisation |
| US9119866B2 (en) | 2008-04-08 | 2015-09-01 | Huiru Wang | Glycan-based drugs, therapies and biomarkers |
| JP5788312B2 (ja) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達 |
| US7981625B2 (en) | 2008-04-15 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Prostate cancer glycan markers and autoantibody signatures |
| US20120039984A1 (en) | 2008-07-03 | 2012-02-16 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| WO2011031472A2 (fr) | 2009-08-25 | 2011-03-17 | The Johns Hopkins University | Détection d'auto-anticorps pour des glycanes spécifiques en tant que tests de diagnostic pour des maladies auto-immunes |
| AU2010313282A1 (en) * | 2009-10-30 | 2012-05-24 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
| WO2011101870A1 (fr) | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Protéines de fusion utilisées pour le traitement de la sclérose en plaques et d'autres maladies auto-immunes |
| CA2801922A1 (fr) | 2010-06-11 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Constructions glycopeptidiques multivalentes et leurs utilisations |
| ES2607087T3 (es) | 2010-12-15 | 2017-03-29 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Método para suprimir una respuesta inmunitaria |
| WO2013044044A2 (fr) | 2011-09-23 | 2013-03-28 | President And Fellows Of Harvard College | Méthodes de traitement de stéatose hépatique par des composés contenant du glycane issu d'helminthe |
| EP2698636A1 (fr) | 2012-08-13 | 2014-02-19 | Fundació Institut d'Investigació Biomèdica de Bellvitge | Procédés et réactifs pour la prévention et/ou le traitement d'un rejet de greffe |
| MX363511B (es) | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
| EP2727597A1 (fr) | 2012-11-06 | 2014-05-07 | Centre National de la Recherche Scientifique (CNRS) | Hydrogel sensible au glucose comprenant de l'acide hyaluronique (ha) greffé pba |
| SG11201508803RA (en) | 2013-04-26 | 2015-11-27 | Agency Science Tech & Res | Tailoring multivalent interactions of biopolymers with a polyproline scaffol |
| WO2015007326A1 (fr) | 2013-07-18 | 2015-01-22 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Agents comprenant une partie alpha-galactosyle terminale destinée à être utilisé dans la prévention et/ou le traitement de maladies inflammatoires |
| WO2015116775A1 (fr) | 2014-01-30 | 2015-08-06 | Trudeau Institute | Nanoparticules pour stimulation immunitaire |
| CA2940579A1 (fr) * | 2014-03-13 | 2015-09-17 | Universitaet Basel | Ligands glucidiques qui se lient aux anticorps igm contre la glycoproteine associee a la myeline |
| EP3350193B1 (fr) | 2015-09-16 | 2020-12-23 | Universität Basel | Ligands glucidiques qui se lient à des anticorps contre des glycoepitopes de glycosphingolipides |
-
2015
- 2015-03-12 CA CA2940579A patent/CA2940579A1/fr not_active Abandoned
- 2015-03-12 RU RU2016134035A patent/RU2760005C2/ru active
- 2015-03-12 KR KR1020167025624A patent/KR20160132034A/ko active IP Right Grant
- 2015-03-12 US US15/124,913 patent/US9994605B2/en active Active
- 2015-03-12 AU AU2015228870A patent/AU2015228870B2/en not_active Ceased
- 2015-03-12 ES ES15709483T patent/ES2865148T3/es active Active
- 2015-03-12 MX MX2016011859A patent/MX2016011859A/es unknown
- 2015-03-12 PT PT157094830T patent/PT3116887T/pt unknown
- 2015-03-12 EP EP15709483.0A patent/EP3116887B1/fr active Active
- 2015-03-12 CN CN201580013911.0A patent/CN106103461B/zh not_active Expired - Fee Related
- 2015-03-12 SG SG11201607484RA patent/SG11201607484RA/en unknown
- 2015-03-12 EP EP21157009.8A patent/EP3915999A1/fr not_active Withdrawn
- 2015-03-12 WO PCT/EP2015/055140 patent/WO2015136027A1/fr active Application Filing
- 2015-03-12 DK DK15709483.0T patent/DK3116887T3/da active
- 2015-03-12 SI SI201531580T patent/SI3116887T1/sl unknown
- 2015-03-12 PL PL15709483T patent/PL3116887T3/pl unknown
- 2015-03-12 RS RS20210472A patent/RS61722B1/sr unknown
- 2015-03-12 JP JP2016557034A patent/JP6502374B2/ja not_active Expired - Fee Related
- 2015-03-12 LT LTEP15709483.0T patent/LT3116887T/lt unknown
- 2015-03-12 HU HUE15709483A patent/HUE054034T2/hu unknown
- 2015-03-12 CN CN201910305446.8A patent/CN110204582A/zh active Pending
-
2016
- 2016-08-18 IL IL247355A patent/IL247355B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,422 patent/US10662212B2/en not_active Expired - Fee Related
-
2019
- 2019-11-27 AU AU2019271964A patent/AU2019271964B2/en not_active Ceased
-
2020
- 2020-04-14 US US16/848,268 patent/US11220523B2/en active Active
-
2021
- 2021-04-08 HR HRP20210562TT patent/HRP20210562T1/hr unknown
- 2021-04-15 CY CY20211100331T patent/CY1124344T1/el unknown
- 2021-11-30 US US17/538,752 patent/US20220185838A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247355B (en) | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein | |
| IL285287B1 (en) | Antibodies to tigit | |
| IL282403A (en) | Antibodies against PD-1 | |
| IL284336B (en) | Treatment using antibodies that bind to ctla4 | |
| HK1252262A1 (zh) | 結合抗糖鞘脂糖蛋白表位抗體的碳水化合物配體 | |
| IL261188A (en) | Antibodies against tigit | |
| IL251963A0 (en) | Anti-1-pd antibodies | |
| HK1256300A1 (zh) | 特異性地結合至tl1a的抗體 | |
| AP2015008709A0 (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
| IL251676A0 (en) | Antibodies that bind to ccr6 and their uses | |
| PL2970503T3 (pl) | Przeciwciała monoklonalne przeciw-(+) --metamfetaminie | |
| SG11201604503XA (en) | Cytotoxic antibody | |
| GB201419087D0 (en) | Anti-PD-1 antibodies | |
| GB201419080D0 (en) | Anti-PD-1 antibodies |